Fibronostics Expands U.S. Operations with Strategic Acquisition of Stone Clinical Laboratories

Fibronostics, a leading name in non-invasive diagnostics, has recently finalized its acquisition of Stone Clinical Laboratories, LLC. This move is set to significantly enhance Fibronostics' operational capacity and innovation within the realm of metabolic and liver disease diagnostics.

The acquisition underscores a crucial step for Fibronostics as it seeks to advance diagnostics related to metabolic dysfunction-associated steatohepatitis (MASH) and metabolic dysfunction-associated steatotic liver disease (MASLD). As the demand for effective diagnostics in this area continues to rise, this acquisition positions Fibronostics at the forefront of meeting these healthcare needs.

Within the context of recent industry advancements—such as the FDA's endorsements of new treatments from Madrigal Pharmaceuticals and Novo Nordisk, as well as Roche's strategic acquisition of 89Bio—the need for reliable and scalable diagnostic methods has never been more pronounced. These events highlight the urgency for early patient identification and proactive disease management.

Brock Smith, the CEO of Fibronostics, articulated the strategic value of this acquisition. He stated, "With the integration of Stone Clinical Laboratories, we significantly enhance our laboratory capabilities across the U.S. This strengthens our innovative drive in non-invasive diagnostics and positions us to collaborate more effectively with pharmaceutical partners tackling the global challenges of MASH and MASLD."

The technical expertise and diverse testing capabilities brought in by Stone Clinical Laboratories will complement Fibronostics' existing digital platforms, such as LIVERFASt®. Together, they aim to expedite the development of biomarkers, research and development programs, and clinical validation studies, all of which support therapeutic advancements and patient management improvements.

Smith further emphasized the importance of this acquisition by noting, "Therapeutic innovations in MASH and MASLD are transforming liver care. As the spectrum of treatment options broadens, the demand for precise and accessible diagnostics escalates. This acquisition ensures Fibronostics is well-equipped to deliver scalable solutions that integrate diagnostics and treatment pathways."

This acquisition is more than just a strengthening of Fibronostics' presence in the U.S. It represents a strategic milestone that enables the organization to forge new partnerships with biopharmaceutical innovators, healthcare systems, and payers. The shared goal is to foster early detection and improve health outcomes for patients suffering from liver-related diseases on a global scale.

About Fibronostics

Fibronostics is recognized globally as a pioneer in health technology, focusing on non-invasive diagnostic solutions specifically for chronic diseases. With a keen emphasis on liver health and metabolic disorders, its flagship solution, LIVERFASt®, enables healthcare professionals to evaluate liver function rapidly and accurately across diverse patient populations. The company collaborates with international pharmaceutical firms, diagnostic laboratories, and healthcare providers to advance the frontiers of liver diagnostics, ultimately aiming to bolster patient care outcomes worldwide.